CRSP CRISPR Therapeutics AG - Common Shares
$52.78
株価 · 8月 18, 2026
ファンダメンタルズ（時点） 8月 3, 2026
52週レンジ
$44–$78
25% of range
アナリスト評価
HOLD
29 analysts
目標株価
$88
+66% upside
P/E (TTM)
-8.2
ROE
-32.0%
純利益率
-16569.8%
CRISPR Therapeutics AG - Common Shares について Wikipediaからの企業概要
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
続きを読む
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
CRSP 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
株価
$52.77
時価総額
$5.06B
P/E (TTM)
-8.2
EPS（TTM）
$-6.47
収益（TTM）
$4M
配当利回り
—
ROE
-32.0%
負債/自己資本
—
52週レンジ
$44 – $78
CRSP 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
Configure
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
収益と純利益
$4M
2016-12-31
→
2025-12-31
EPS
$-6.47
2017-12-31
→
2025-12-31
フリーキャッシュフロー
$-346M
2016-12-31
→
2025-12-31
利益率
-16569.8%
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
指標
5年トレンド
CRSP
競合中央値
P/E (TTM)
-8.2
—
P/S (TTM) (株価売上高倍率（TTM）)
1441.8
56.3
P/B (株価純資産倍率)
2.6
3.0
Price / FCF (株価FCF倍率)
-14.6
—
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
指標
5年トレンド
CRSP
競合中央値
Operating Margin (営業利益率)
-18933.7%
—
Net Profit Margin (純利益率)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
指標
5年トレンド
CRSP
競合中央値
Current Ratio (流動比率)
13.3
6.7
Quick Ratio (クイックレシオ)
13.2
—
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
指標
5年トレンド
CRSP
競合中央値
Revenue YoY (収益（前年比）)
-90.6%
—
Revenue CAGR 3Y (収益（3年CAGR）)
43.1%
—
Revenue CAGR 5Y (収益（5年CAGR）)
37.3%
—
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
指標
5年トレンド
CRSP
競合中央値
CRSP アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
買い
29 アナリスト
- 強い買い 6 20.7%
- 買い 11 37.9%
- 保有 12 41.4%
- 売り 0 0.0%
- 強い売り 0 0.0%
12ヶ月目標株価
18 アナリスト · 2026-08-15
中央値
$80.00
現在
$52.77
安値
$44.00
高値
$291.00
中央値ターゲット
$80.00
+51.6%
平均値ターゲット
$87.56
+65.9%
決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
平均サプライズ
0.01%
| 期間 | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|
| 2026年6月30日 | $-0.94 | $-1.22 | 0.28% |
| 2026年3月31日 | $-1.28 | $-1.25 | -0.03% |
| 2025年12月31日 | $-1.37 | $-1.18 | -0.19% |
| 2025年9月30日 | $-1.17 | $-1.29 | 0.12% |
| 2025年6月30日 | $-1.29 | $-1.45 | 0.16% |
| 2025年3月31日 | $-1.58 | $-1.28 | -0.30% |
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書 15
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
貸借対照表 25
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
キャッシュフロー 14
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
収益性 7
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
流動性と支払能力 2
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
効率性 2
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
成長率 3
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
バリュエーション（TTM） 10
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
損益計算書 14
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
貸借対照表 25
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
キャッシュフロー 11
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
収益性 7
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
流動性と支払能力 2
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
効率性 2
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
バリュエーション（TTM） 10
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
損益計算書
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 収益 | $4M | $37M | $371M | $1M | $915M |
| 営業利益率 % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| 純利益 | $-582M | $-366M | $-154M | $-650M | $378M |
| 希薄化後EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
貸借対照表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流動比率 | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| クイックレシオ | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
キャッシュフロー
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| フリーキャッシュフロー | $-346M | $-145M | $-270M | $-533M | $457M |
最新ニュース この会社に言及した最近の見出し
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- CRISPR Therapeutics株はとてつもなく安い -- アナリストが437%の上昇ポテンシャルを見込む理由
- メガキャップ・グロース・リーダーシップか、小型株グロースの可能性か？ VUG vs. VBK
- 1 ウォール街のトップアナリストは、CRISPRセラピューティクスが2倍以上になる可能性があると考えています。今すぐ株を手に取るべきでしょうか？
- 注目すべきETFの資金流出を検出 - ARKK、CRSP、TEM、HOOD
- このバイオテクノロジー企業は、その治療領域全体を再定義する可能性のあるパイプラインを持っています
- キャシー・ウッド、掘り出し物探し：彼女が最近購入した2銘柄
- このバイオテクノロジー株は、100万ドルを生み出すポジションを構築するための最良の選択肢でしょうか？
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
📊
あなたにとって重要なメトリクスを選択 — 上記の決算詳細の任意の行の横にある➕をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
機関投資家（13F） 573 提出者 · $3.3B合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
機関投資家の動向 — Q2 2026 対 前四半期
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 89 (0 前期比) | 47 (-13 前期比) | 148 (-24 前期比) | 145 (+21 前期比) | +5.4M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| ARK Investment Management LLC | $515,999,631 | 9,460,939 | 15.58% | 株式数 |
| Orbis Allan Gray Ltd | $296,334,582 | 5,433,344 | 8.95% | 株式数 |
| Capital World Investors | $259,039,094 | 4,749,525 | 7.82% | 株式数 |
| STATE STREET CORP | $235,703,664 | 4,321,666 | 7.12% | 株式数 |
| GSK plc | $175,652,997 | 3,220,627 | 5.30% | 株式数 |
| GEODE CAPITAL MANAGEMENT, LLC | $117,453,717 | 2,153,015 | 3.55% | 株式数 |
| SR One Capital Management, LP | $111,194,134 | 2,038,763 | 3.36% | 株式数 |
| TWO SIGMA INVESTMENTS, LP | $108,459,389 | 1,988,621 | 3.27% | 株式数 |
| Sumitomo Mitsui Trust Group, Inc. | $93,848,832 | 1,720,734 | 2.83% | 株式数 |
| Amova Asset Management Americas, Inc. | $93,762,487 | 1,720,097 | 2.83% | 株式数 |
| EcoR1 Capital, LLC | $75,771,113 | 1,389,276 | 2.29% | 株式数 |
| Capital International Investors | $69,178,918 | 1,268,407 | 2.09% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $64,457,935 | 1,181,847 | 1.95% | 株式数 |
| NEA Management Company, LLC | $57,734,408 | 1,058,570 | 1.74% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57,694,430 | 1,057,837 | 1.74% | 株式数 |
| FMR LLC | $53,577,751 | 982,357 | 1.62% | 株式数 |
| D. E. Shaw & Co., Inc. | $48,748,506 | 893,812 | 1.47% | 株式数 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35,380,807 | 648,713 | 1.07% | 株式数 |
| UBS Group AG | $32,419,612 | 594,419 | 0.98% | 株式数 |
| VANGUARD FIDUCIARY TRUST CO | $31,089,982 | 570,040 | 0.94% | 株式数 |
| VANGUARD GROUP INC | $27,714,225 | 528,494 | 0.84% | 株式数 |
| CITADEL ADVISORS LLC | $25,404,514 | 465,796 | 0.77% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $23,509,740 | 431,055 | 0.71% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23,298,288 | 427,178 | 0.70% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $20,836,025 | 382,032 | 0.63% | 株式数 |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20,833,789 | 381,991 | 0.63% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18,456,336 | 338,400 | 0.56% | プットオプション |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17,763,678 | 325,700 | 0.54% | コールオプション |
| Logos Global Management LP | $16,362,000 | 300,000 | 0.49% | 株式数 |
| CITADEL ADVISORS LLC | $15,822,054 | 290,100 | 0.48% | プットオプション |
| Squarepoint Ops LLC | $15,641,472 | 286,789 | 0.47% | 株式数 |
| NORGES BANK | $14,767,032 | 270,756 | 0.45% | 株式数 |
| CITADEL ADVISORS LLC | $13,973,148 | 256,200 | 0.42% | コールオプション |
| GOLDMAN SACHS GROUP INC | $12,748,193 | 233,740 | 0.38% | 株式数 |
| JANE STREET GROUP, LLC | $12,566,016 | 230,400 | 0.38% | コールオプション |
| PEAK6 LLC | $11,633,382 | 213,300 | 0.35% | プットオプション |
| Swiss National Bank | $9,228,168 | 169,200 | 0.28% | 株式数 |
| Susquehanna Portfolio Strategies, LLC | $8,945,978 | 164,026 | 0.27% | 株式数 |
| TWO SIGMA ADVISERS, LP | $8,516,256 | 162,400 | 0.26% | 株式数 |
| LPL Financial LLC | $8,376,280 | 153,581 | 0.25% | 株式数 |
| Bank of New York Mellon Corp | $8,337,366 | 152,867 | 0.25% | 株式数 |
| DIMENSIONAL FUND ADVISORS LP | $8,301,261 | 152,205 | 0.25% | 株式数 |
| Versant Venture Management, LLC | $8,117,243 | 148,831 | 0.25% | 株式数 |
| Pictet Asset Management Holding SA | $7,989,776 | 142,213 | 0.24% | 株式数 |
| Life Cycle Investment Partners Ltd | $7,836,962 | 143,692 | 0.24% | 株式数 |
| TD Asset Management Inc | $7,777,513 | 142,602 | 0.23% | 株式数 |
| AMERICAN CENTURY COMPANIES INC | $7,606,257 | 139,462 | 0.23% | 株式数 |
| RAYMOND JAMES FINANCIAL INC | $7,230,750 | 132,577 | 0.22% | 株式数 |
| RHUMBLINE ADVISERS | $6,627,197 | 121,511 | 0.20% | 株式数 |
| SFE Investment Counsel | $6,229,434 | 16,700 | 0.19% | プットオプション |
| Private Advisor Group, LLC | $6,060,980 | 111,129 | 0.18% | 株式数 |
| EverSource Wealth Advisors, LLC | $6,032,669 | 110,610 | 0.18% | 株式数 |
| CONGRESS ASSET MANAGEMENT CO | $5,969,567 | 109,453 | 0.18% | 株式数 |
| BlackRock, Inc. | $5,937,061 | 108,857 | 0.18% | 株式数 |
| D. E. Shaw & Co., Inc. | $5,901,228 | 108,200 | 0.18% | コールオプション |
| Campbell & CO Investment Adviser LLC | $5,864,632 | 107,529 | 0.18% | 株式数 |
| JANE STREET GROUP, LLC | $5,852,142 | 107,300 | 0.18% | プットオプション |
| California Public Employees Retirement System | $5,599,567 | 102,669 | 0.17% | 株式数 |
| CAPITAL INTERNATIONAL SARL | $5,521,521 | 101,238 | 0.17% | 株式数 |
| Affinity Asset Advisors, LLC | $5,454,000 | 100,000 | 0.16% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $5,439,011 | 114,337 | 0.16% | 株式数 |
| CLOUGH CAPITAL PARTNERS L P | $5,363,300 | 98,337 | 0.16% | 株式数 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5,172,465 | 94,838 | 0.16% | 株式数 |
| Slow Capital, Inc. | $5,066,439 | 92,894 | 0.15% | 株式数 |
| CAPITAL FUND MANAGEMENT S.A. | $4,867,258 | 89,242 | 0.15% | 株式数 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4,815,606 | 101,232 | 0.15% | 株式数 |
| VANGUARD ASSET MANAGEMENT, Ltd | $4,720,437 | 86,550 | 0.14% | 株式数 |
| GROUP ONE TRADING LLC | $4,638,082 | 85,040 | 0.14% | 株式数 |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4,575,742 | 83,897 | 0.14% | 株式数 |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4,502,113 | 82,547 | 0.14% | 株式数 |
| Concurrent Investment Advisors, LLC | $4,497,728 | 82,467 | 0.14% | 株式数 |
| WELLS FARGO & COMPANY/MN | $4,309,151 | 79,009 | 0.13% | 株式数 |
| Fisher Asset Management, LLC | $4,251,957 | 77,960 | 0.13% | 株式数 |
| Trexquant Investment LP | $4,225,268 | 77,471 | 0.13% | 株式数 |
| COMMONWEALTH EQUITY SERVICES, LLC | $4,194,122 | 76,900 | 0.13% | 株式数 |
| JONES FINANCIAL COMPANIES LLLP | $4,055,652 | 73,847 | 0.12% | 株式数 |
| Man Group plc | $3,992,001 | 73,194 | 0.12% | 株式数 |
| PEAK6 LLC | $3,834,162 | 70,300 | 0.12% | コールオプション |
| ENVESTNET ASSET MANAGEMENT INC | $3,822,196 | 70,081 | 0.12% | 株式数 |
| ALGERT GLOBAL LLC | $3,593,095 | 65,880 | 0.11% | 株式数 |
| Walleye Trading LLC | $3,528,738 | 64,700 | 0.11% | プットオプション |
| MILLENNIUM MANAGEMENT LLC | $3,146,958 | 57,700 | 0.10% | コールオプション |
| CAPITAL INTERNATIONAL LTD /CA/ | $3,057,840 | 56,066 | 0.09% | 株式数 |
| NOMURA HOLDINGS INC | $3,055,713 | 56,027 | 0.09% | 株式数 |
| Rafferty Asset Management, LLC | $3,045,132 | 55,833 | 0.09% | 株式数 |
| Green Alpha Advisors, LLC | $3,043,550 | 55,804 | 0.09% | 株式数 |
| Walleye Trading LLC | $3,005,154 | 55,100 | 0.09% | コールオプション |
| Caption Management, LLC | $2,999,700 | 55,000 | 0.09% | コールオプション |
| MetLife Investment Management, LLC | $2,958,413 | 54,243 | 0.09% | 株式数 |
| BENJAMIN EDWARDS INC | $2,956,845 | 54,216 | 0.09% | 株式数 |
| Quantinno Capital Management LP | $2,869,349 | 52,610 | 0.09% | 株式数 |
| Cetera Investment Advisers | $2,856,133 | 52,368 | 0.09% | 株式数 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,788,521 | 51,128 | 0.08% | 株式数 |
| CITIGROUP INC | $2,781,540 | 51,000 | 0.08% | コールオプション |
| CITIGROUP INC | $2,781,540 | 51,000 | 0.08% | プットオプション |
| WOLVERINE ASSET MANAGEMENT LLC | $2,727,000 | 50,000 | 0.08% | プットオプション |
| OSAIC HOLDINGS, INC. | $2,693,150 | 49,381 | 0.08% | 株式数 |
| Privium Fund Management B.V. | $2,452,882 | 44,974 | 0.07% | 株式数 |
| CANADA PENSION PLAN INVESTMENT BOARD | $2,394,306 | 43,900 | 0.07% | 株式数 |
| TUDOR INVESTMENT CORP ET AL | $2,318,604 | 42,512 | 0.07% | 株式数 |
企業インサイダー 32 人のインサイダー · 12人の役員 · 16人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 2026年3月20日 M | 255,501 | 0 | 9 | $-10,756,932 |
| Brendan Smith | Chief Financial Officer | 2023年2月18日 M | 5,072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 2021年3月11日 M | 1,891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 2025年3月20日 M | 10,544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 2022年8月16日 A | 26,797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 2026年5月29日 A | 19,357 | 1 | 2 | $-312,892 |
| James R. Kasinger | General Counsel and Secretary | 2026年5月29日 A | 94,308 | 0 | 5 | $-645,902 |
| Phuong Khanh Morrow | Chief Medical Officer | 2023年10月13日 A | 4,411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 2021年12月3日 M | 52,364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 2018年1月16日 M | 25,204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 2017年6月15日 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 2016年10月24日 C | 505,617 | 0 | 0 | $0 |
| Christian Rommel | 取締役 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | 取締役 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Douglas A Treco | 取締役 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Briggs Morrison | 取締役 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Katherine A High | 取締役 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Ali Behbahani | 取締役 | 2026年6月5日 A | 14 | 0 | 0 | $0 |
| John Greene | 取締役 | 2026年6月5日 A | 7,000 | 0 | 0 | $0 |
| Simeon George | 取締役 | 2026年6月5日 A | 1,730,179 | 0 | 0 | $0 |
| Maria Fardis | 取締役 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | 取締役 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | 取締役 | 2022年6月9日 A | 148,831 | 0 | 0 | $0 |
| Pablo J Cagnoni | 取締役 | 2019年11月19日 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | 取締役 | 2018年12月18日 S | 1,171,268 | 0 | 0 | $0 |
| Thomas Woiwode | 取締役 | 2018年6月15日 A | 640,014 | 0 | 0 | $0 |
| Anthony N Coles | 取締役 | 2017年5月31日 A | 70,000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10%オーナー | 2017年12月4日 S | 3,722,534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10%オーナー | 2016年10月24日 C | 744,380 | 0 | 0 | $0 |
| GSK plc | 10%オーナー | 2016年10月24日 C | 3,220,627 | 0 | 0 | $0 |
| Raju Prasad | — | 2026年8月7日 G | 14,815 | 0 | 10 | $-5,100,841 |
| Rodger Novak | — | 2021年6月30日 S | 573,007 | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
アクティビストおよび5%超のオーナー 6保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 提出書類 | 2021年2月16日 | — | 初回提出 | — | SEC |
| GlaxoSmithKline plc ×5 提出書類 | 2020年7月10日 | — | 初回提出 | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 提出書類 | 2020年2月4日 | — | 初回提出 | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 提出書類 | 2019年6月7日 | — | 初回提出 | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 提出書類 | 2018年2月8日 | — | 初回提出 | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 提出書類 | 2018年1月16日 | — | 初回提出 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF保有状況 32のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| GNOM · Global X Funds | 3.85% | 38,191 NS | 2026年5月31日 | N-PORT |
| IDNA · iShares Trust | 1.63% | 62,247 SH | 2026年8月8日 | 日次 |
| LABU · Direxion Shares ETF Trust | 0.98% | 97,235 NS | 2026年4月30日 | N-PORT |
| IBB · iShares Trust | 0.36% | 658,537 SH | 2026年8月8日 | 日次 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.35% | 5,248 SH | 2026年8月8日 | 日次 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.28% | 70,696 SH | 2026年8月8日 | 日次 |
| IWN · iShares Trust | 0.27% | 752,223 SH | 2026年8月8日 | 日次 |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.21% | 104,016 NS | 2026年5月31日 | N-PORT |
| ISCV · iShares Trust | 0.15% | 20,568 SH | 2026年8月8日 | 日次 |
| IWM · iShares Trust | 0.15% | 2,353,025 SH | 2026年8月8日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.15% | 536,446 SH | 2026年8月8日 | 日次 |
| RSSL · Global X Funds | 0.15% | 39,589 NS | 2026年4月30日 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.10% | 6,636 SH | 2026年8月8日 | 日次 |
| ISCB · iShares Trust | 0.07% | 4,136 SH | 2026年8月8日 | 日次 |
| SMLF · iShares Trust | 0.07% | 57,970 SH | 2026年8月8日 | 日次 |
| VXF · VANGUARD INDEX FUNDS | 0.06% | 1,106,455 SH | 2026年8月8日 | 日次 |
| ESML · iShares Trust | 0.06% | 33,283 SH | 2026年8月8日 | 日次 |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.06% | 108 NS | 2026年5月31日 | N-PORT |
| WSML · iShares Trust | 0.04% | 5,486 SH | 2026年8月8日 | 日次 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 13,170 SH | 2026年8月8日 | 日次 |
| IWO · iShares Trust | 0.04% | 109,974 SH | 2026年8月8日 | 日次 |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 1,736 SH | 2026年8月8日 | 日次 |
| XT · iShares Trust | 0.03% | 21,837 SH | 2026年8月8日 | 日次 |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.03% | 3,509 NS | 2026年5月31日 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 7,774 SH | 2026年8月8日 | 日次 |
| ESGV · VANGUARD WORLD FUND | 0.01% | 20,627 SH | 2026年8月8日 | 日次 |
| IYY · iShares Trust | 0.01% | 4,231 SH | 2026年8月8日 | 日次 |
| ITOT · iShares Trust | 0.01% | 128,511 SH | 2026年8月8日 | 日次 |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.01% | 15,609 NS | 2026年5月31日 | N-PORT |
| IWV · iShares Trust | 0.01% | 25,457 SH | 2026年8月8日 | 日次 |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.00% | 289 NS | 2026年5月31日 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 75,392 SH | 2026年8月8日 | 日次 |